血脑障壁药物递送市场－全球产业规模、份额、趋势、机会及预测（按技术、应用、地区和竞争格局划分，2021-2031年）

全球血脑障壁渗透性输送市场预计将从 2025 年的 19.5 亿美元成长到 2031 年的 26.9 亿美元，复合年增长率为 5.51%。

此细分市场包括旨在将治疗药物输送穿过半透性内皮屏障（该屏障将中枢神经系统与体循环分隔开来）的专用技术和製剂。全球神经退化性疾病盛行率的不断上升以及对这些传统上难以治癒的疾病进行非侵入性治疗方法的需求，是推动该市场成长的主要因素。世界神经病学联合会 (WFN) 预测，到 2024 年，神经系统疾病将成为全球首要致残原因，影响超过 30 亿人，凸显了开发能够有效治疗复杂中枢神经系统疾病的先进给药系统的紧迫性。

然而，血脑障壁高度复杂的生理特性为市场拓展带来了巨大挑战。它天然地阻挡了大多数小分子和大分子药物。这种选择性渗透性导致候选药物在临床试验中失败率极高，因此，工程化载体必须在不影响安全性的前提下可靠地穿过此屏障。因此，如何使药物在大脑中达到足够的浓度仍然是研发人员将新型神经治疗药物商业化的主要障碍。

市场驱动因素

全球神经退化性疾病和中枢神经系统（CNS）疾病的日益流行是推动血脑障壁（BBB）药物递送市场发展的主要因素。不断增长的患者群体迫切需要有效的治疗药物转运机制。阿兹海默症和脑肿瘤等疾病日益加重的全球负担，给药物研发人员带来了越来越大的压力，他们需要克服限制全身治疗效果的内皮细胞屏障。根据阿兹海默症协会于2025年4月发布的《2025年阿兹海默症最新进展报告》，目前约有720万65岁及以上的美国人患有老年痴呆症失智症，凸显了脑渗透性治疗方法的迫切需求。此外，更广泛的肿瘤学领域也支持这项需求。全身性癌症经常转移到中枢神经系统，据美国癌症协会称，预计到 2025 年，美国将诊断出 2,041,910总合新的癌症病例，这推动了对能够到达颅内恶性肿瘤的输送技术的需求。

第二个关键驱动因素是策略联盟的兴起，这些联盟加速了药物递送平台的商业化进程，透过大量的资金注入和技术协同效应效应，使实验性、突破性的技术能够转化为临床应用。大型製药企业正越来越多地与专业生物技术公司合作，将专有的穿梭平台整合到其大分子药物研发管线中，从而降低中枢神经系统（CNS）药物研发的高风险。罗氏日益重视下一代递送方式就是这一趋势的一个显着例证。根据该公司2025年11月发布的新闻稿，Manifold Bio已与罗氏达成一项价值高达20亿美元的策略联盟，共同开发血脑障壁穿梭系统。此类高价值协议验证了这些递送系统的商业性潜力，并确保创新的递送方法能够获得必要的投资，最终推向市场。

市场挑战

血脑障壁的生理复杂性是拓展药物递送市场的主要障碍。这种生物防御机制限制了治疗药物的选择性进入，使得在中枢神经系统内达到所需的药物浓度变得极为困难。因此，製药公司在临床试验中经常遭遇挫折，因为设计的载体往往无法在保持安全性和有效性的同时克服这一屏障。这项技术障碍增加了研发所需的时间和资金，使得神经系统药物研发计画比其他治疗领域的风险显着更高。

这种高风险状况与新型治疗方法的商业化率较低有直接关係。当药物递送机制无法有效输送药物时，整个研发项目往往会停滞，对研发者造成重大经济损失。根据美国药品研究与製造商协会（PhRMA）预测，到2024年，由于中枢神经系统（CNS）研究固有的难度，进入开发平臺的新型神经系统药物的临床成功率将低于6%。如此低的核准机率限制了新产品的上市，并限制了全球市场的潜在收入成长。

市场趋势

受体介导的胞吞转运技术平台的进步正在从根本上改变市场格局，使大分子治疗药物能够通过内源性穿梭系统跨越内皮屏障。研发人员正逐步摒弃侵入性给药方式，转而寻求活化天然转运机制并绕过外排放泵的方法，例如设计能够与转铁蛋白等受体结合的双特异性抗体。随着大型製药公司寻求将这些穿梭平台整合到其生物製药产品线中，以确保治疗药物的可及性，这项技术变革正在推动高价值整合。根据艾伯维公司2024年12月发布的新闻稿“艾伯维完成对Ariada Therapeutics的收购”，该公司以14亿美元收购了Ariada Therapeutics，主要目的是获得其专有的MODEL平台。此平台利用高亲和性转铁蛋白受体偶联物递送多种中枢神经系统（CNS）候选药物。

同时，基于奈米技术的载体系统的广泛应用，使得将包括mRNA和基因疗法在内的脆弱基因药物直接递送至脑组织成为可能。研究日益聚焦于具有优化表面化学性质的脂质奈米颗粒（LNP），这些颗粒能够穿透血脑障壁的紧密连接，且不影响所包裹药物的稳定性。这些先进的载体克服了病毒载体的局限性，能够降低免疫抗原性，并为复杂的製剂提供更高的载药量。在2025年2月发表于《自然·材料》（Nature Materials）杂誌的一篇题为“用于中枢神经系统mRNA递送的血脑障壁穿透性脂质奈米颗粒”的研究中，西奈山伊坎医学院的一个研究团队成功开发了一种新型脂质奈米颗粒系统，与现有的批准製剂相比，该系统实现了更高效的FDAmRNA系统实现了更高效的FDAmRNA系统实现了更高效的核准系统实现了更高效的FDAmRNA系统实现了更高效的FDAmRNA系统实现了更高效的FDAmRNA系统实现了更高效的FDAmRNA系统实现了更高效的FDAmRNA系统实现了更高效的FDAmRNA系统实现了更高效的FDAmRNA系统实现了更高效的FDAmRNA系统。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球血脑障壁药物递送市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 透过技术手段（特洛伊木马方法、双特异性抗体RMT方法、血脑障壁渗透性改善、被动扩散等）
  • 依应用领域（阿兹海默症、癫痫、帕金森氏症、多发性硬化症、韩特氏症、脑肿瘤等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美血脑障壁药物递送市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲血脑障壁药物递送市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区血脑障壁药物递送市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲血脑障壁药物递送市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲血脑障壁药物递送市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球血脑障壁药物递送市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Ossianix Inc.
• Insightec Ltd.
• F. Hoffmann-La Roche Ltd
• JCR Pharmaceuticals Co., Ltd.
• Lauren Sciences LLC
• Bioasis Technologies Inc.
• Ceres Brain Therapeutics
• Nanomerics Ltd.
• NEUWAY Pharma GmbH
• Genervon Biopharmaceuticals LLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Drug Delivery Across Blood Brain Barrier Market is projected to expand from USD 1.95 Billion in 2025 to USD 2.69 Billion by 2031, reflecting a compound annual growth rate of 5.51%. This sector encompasses specialized technologies and formulations designed to transport therapeutic agents through the semi-permeable endothelial boundary separating the central nervous system from systemic circulation. The market is fundamentally supported by the increasing global prevalence of neurodegenerative diseases and the critical necessity for non-invasive mechanisms to treat conditions previously considered inaccessible. According to the World Federation of Neurology, in 2024, neurological disorders were the leading cause of disability worldwide and affected over three billion individuals, underscoring the urgent demand for advanced delivery systems capable of ensuring therapeutic efficacy for complex central nervous system conditions.

However, the profound physiological complexity of the blood-brain barrier represents a significant challenge impeding market expansion, as it naturally excludes the vast majority of small and large molecule drugs. This selective permeability results in an exceptionally high failure rate for drug candidates during clinical trials, as engineered carriers must successfully traverse the barrier without compromising safety. Consequently, the scientific difficulty in achieving sufficient drug concentration within the brain remains a primary obstacle for developers aiming to commercialize novel neurological therapies.

Market Driver

The rising global prevalence of neurodegenerative and CNS disorders serves as the primary catalyst propelling the drug delivery across the blood-brain barrier market, as the escalating patient population intensifies the urgent need for effective therapeutic transport mechanisms. As the global burden of conditions like Alzheimer's disease and brain tumors expands, pharmaceutical developers are under increasing pressure to overcome the endothelial impediments that restrict the efficacy of systemic treatments. According to the Alzheimer's Association's '2025 Alzheimer's Disease Facts and Figures' report released in April 2025, an estimated 7.2 million Americans aged 65 and older are currently living with Alzheimer's dementia, highlighting the critical demand for brain-penetrant therapies. Furthermore, the broader oncology sector reinforces this necessity, as systemic cancers frequently metastasize to the central nervous system; according to the American Cancer Society, in 2025, a total of 2,041,910 new cancer cases are projected to be diagnosed in the United States, driving the requirement for delivery technologies that can reach intracranial malignancies.

Strategic collaborations to accelerate delivery platform commercialization have emerged as a second decisive driver, enabling the translation of experimental barrier-crossing technologies into clinical realities through significant capital infusion and technical synergy. Large pharmaceutical entities are increasingly partnering with specialized biotech firms to integrate proprietary shuttle platforms with their large molecule pipelines, thereby mitigating the high risks associated with CNS drug development. A notable instance of this trend occurred when Roche strengthened its commitment to next-generation delivery modalities; according to Manifold Bio in a November 2025 corporate press release, the company entered a strategic partnership with Roche worth up to $2 billion to develop blood-brain barrier shuttles leveraging in vivo design technologies. Such high-value agreements validate the commercial potential of these delivery systems and ensure that innovative transport methodologies receive the investment necessary to reach the market.

Market Challenge

The physiological complexity of the blood-brain barrier constitutes a primary restraint on the expansion of the drug delivery market. This biological defense mechanism selectively restricts the entry of therapeutic agents, leading to significant difficulties in achieving necessary drug concentrations within the central nervous system. As a result, pharmaceutical companies encounter frequent setbacks during clinical trials, as engineered carriers often fail to navigate the barrier while maintaining safety and efficacy standards. This technical hurdle increases the time and capital required for development, making neurological programs significantly riskier than those in other therapeutic areas.

This elevated risk profile directly correlates with reduced commercialization rates for novel therapies. When delivery mechanisms fail to transport drugs effectively, the entire development program is often terminated, resulting in substantial financial losses for developers. According to the Pharmaceutical Research and Manufacturers of America, in 2024, the inherent difficulties in CNS research resulted in a clinical success rate of less than 6 percent for new neurological medicines entering the development pipeline. This low probability of approval limits the introduction of new products and constrains the potential revenue growth for the global market.

Market Trends

The advancement of receptor-mediated transcytosis platforms is fundamentally altering the market by enabling the transport of large-molecule therapeutics through the endothelial boundary via endogenous shuttle systems. Developers are moving beyond invasive delivery methods, instead engineering bispecific antibodies that bind to receptors such as transferrin to trigger natural transport mechanisms and bypass efflux pumps. This technological shift is driving high-value consolidation as major pharmaceutical companies seek to integrate these shuttle platforms into their biologic pipelines to ensure therapeutic reach. According to AbbVie, in the 'AbbVie Completes Acquisition of Aliada Therapeutics' press release from December 2024, the company acquired Aliada Therapeutics for $1.4 billion primarily to secure its proprietary MODEL platform, which utilizes high-affinity transferrin receptor binders to deliver diverse CNS drug candidates.

Concurrently, the widespread adoption of nanotechnology-based carrier systems is expanding the possibilities for delivering fragile genetic medicines, including mRNA and gene therapies, directly to brain tissue. Research is increasingly focusing on lipid nanoparticles (LNPs) with optimized surface chemistries that can navigate the blood-brain barrier's tight junctions without compromising the stability of the encapsulated payload. These advanced carriers are overcoming the limitations of viral vectors by offering reduced immunogenicity and higher cargo capacity for complex formulations. According to the Icahn School of Medicine at Mount Sinai, in the study 'Blood-brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system' published in 'Nature Materials' in February 2025, researchers successfully developed a novel lipid nanoparticle system that achieved superior mRNA delivery efficiency to the brain compared to existing FDA-approved formulations.

Key Market Players

• Ossianix Inc.
• Insightec Ltd.
• F. Hoffmann-La Roche Ltd
• JCR Pharmaceuticals Co., Ltd.
• Lauren Sciences LLC
• Bioasis Technologies Inc.
• Ceres Brain Therapeutics
• Nanomerics Ltd.
• NEUWAY Pharma GmbH
• Genervon Biopharmaceuticals LLC

Report Scope

In this report, the Global Drug Delivery Across Blood Brain Barrier Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Drug Delivery Across Blood Brain Barrier Market, By Technology

• Trojan Horse Approach
• Bispecific Antibody RMT Approach
• Increasing the Permeability of BBB
• Passive Diffusion
• Others

Drug Delivery Across Blood Brain Barrier Market, By Application

• Alzheimer's Disease
• Epilepsy
• Parkinson's Disease
• Multiple Sclerosis
• Hunter's Syndrome
• Brain Cancer
• Others

Drug Delivery Across Blood Brain Barrier Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Drug Delivery Across Blood Brain Barrier Market.

Available Customizations:

Global Drug Delivery Across Blood Brain Barrier Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Drug Delivery Across Blood Brain Barrier Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Trojan Horse Approach, Bispecific Antibody RMT Approach, Increasing the Permeability of BBB, Passive Diffusion, Others)
  • 5.2.2. By Application (Alzheimer's Disease, Epilepsy, Parkinson's Disease, Multiple Sclerosis, Hunter's Syndrome, Brain Cancer, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Drug Delivery Across Blood Brain Barrier Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Drug Delivery Across Blood Brain Barrier Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Drug Delivery Across Blood Brain Barrier Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Drug Delivery Across Blood Brain Barrier Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Application

7. Europe Drug Delivery Across Blood Brain Barrier Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Drug Delivery Across Blood Brain Barrier Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Application
  • 7.3.2. France Drug Delivery Across Blood Brain Barrier Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Drug Delivery Across Blood Brain Barrier Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Drug Delivery Across Blood Brain Barrier Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Drug Delivery Across Blood Brain Barrier Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Application

8. Asia Pacific Drug Delivery Across Blood Brain Barrier Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Drug Delivery Across Blood Brain Barrier Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Application
  • 8.3.2. India Drug Delivery Across Blood Brain Barrier Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Drug Delivery Across Blood Brain Barrier Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Drug Delivery Across Blood Brain Barrier Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Drug Delivery Across Blood Brain Barrier Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Application

9. Middle East & Africa Drug Delivery Across Blood Brain Barrier Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Drug Delivery Across Blood Brain Barrier Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Drug Delivery Across Blood Brain Barrier Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Drug Delivery Across Blood Brain Barrier Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application

10. South America Drug Delivery Across Blood Brain Barrier Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Drug Delivery Across Blood Brain Barrier Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Drug Delivery Across Blood Brain Barrier Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Drug Delivery Across Blood Brain Barrier Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Drug Delivery Across Blood Brain Barrier Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Ossianix Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Insightec Ltd.
• 15.3. F. Hoffmann-La Roche Ltd
• 15.4. JCR Pharmaceuticals Co., Ltd.
• 15.5. Lauren Sciences LLC
• 15.6. Bioasis Technologies Inc.
• 15.7. Ceres Brain Therapeutics
• 15.8. Nanomerics Ltd.
• 15.9. NEUWAY Pharma GmbH
• 15.10. Genervon Biopharmaceuticals LLC

16. Strategic Recommendations

17. About Us & Disclaimer